A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.

虽然胰 高血糖 素样肽-1受体激动剂（GLP-1 RA）最初开发是用于治疗2型 糖尿病 ，但在研究中，研究人员发现，GLP-1 RA还能够帮助超重和肥胖患者减重，效果十分显著，并且与是否合并糖尿病无关。

Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term.

New research published in JAMA Network Open led by Truveta Research and Ezekiel Emanuel, MD, PhD, Perelman School of Medicine ...

诺和诺德（Novo Nordisk）日前宣布，美国FDA已批准其重磅疗法Ozempic（司美格鲁肽，semaglutide），用于降低2型糖尿病合并慢性肾病（CKD）成年患者的肾病恶化、肾功能衰竭（终末期肾病）以及心血管疾病导致的死亡风险。根据新闻稿 ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform consumers.

The good news is that the risk for thyroid cancer linked to GLP-1 drugs appears low, but higher detections in the first year, ...

In line with trial results, real-world data suggest GLP-1 receptor agonists have certain benefits in patients with moderate to severe chronic kidney disease (CKD).

Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. Unless you ...

THURSDAY, Jan. 30, 2025 (HealthDay News) -- The absolute risk for thyroid cancer is low among patients receiving ...

Investing.com -- ...